Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Gene transfer for studying and treating a connective tissue of a mammalian host

a technology of connective tissue and gene transfer, which is applied in the field of gene transfer for studying and treating the connective tissue of a mammalian host, can solve the problems of less efficient diffusion with the increase of the target molecule size, affecting the therapeutic intervention of arthritis, and affecting the survival rate of the host, so as to prevent arthritis, resist the degradation of cartilage, and improve the survival rate.

Inactive Publication Date: 2006-05-02
UNIVERSITY OF PITTSBURGH
View PDF1 Cites 64 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0032]One ex vivo method of treating a connective tissue disorder disclosed throughout this specification comprises generating a recombinant viral vector which contains at least one DNA sequence encoding a protein or biologically active fragment thereof. This recombinant viral vector is then used to infect a population of in vitro cultured connective tissue cells or non-connective tissue cells, resulting in a population of transduced cells. These transduced cells are then transplanted to the host, for example in a target joint space, bone marrow, or blood stream of a mammalian host, effecting subsequent expression of the protein or protein fragment within the joint space of the host. Expression of the DNA sequence of interest is useful in substantially reducing at least one deleterious joint pathology or indicia of inflammation normally associated with a connective tissue disorder.
[0042]In a specific method disclosed as an example, and not as a limitation to the present invention, a DNA plasmid vector containing the interleukin-1 beta (IL-1β) coding sequence was ligated downstream of the cytomegalovirus (CMV) promoter. This DNA plasmid construction was encapsulated within liposomes and injected intra-articularly into the knee joints of recipient rabbits. IL-1β was expressed and significant amounts of IL-1β were recovered from the synovial tissue. An alternative is injection of the naked plasmid DNA into the knee joint, allowing direct transfection of the DNA into the synovial tissue. Injection of IL-1β into the joint of a mammalian host allows for prolonged study of various joint pathologies and systemic indices of inflammation, as described within this specification.
[0057]It is an object of the present invention to provide a method of introducing by ex vivo or in vivo methods a gene in a mammalian host that is capable of binding to and neutralizing substantially all isoforms of interleukin-1 and thus, substantially resist the degradation of cartilage and protect surrounding soft tissues of the joint space.

Problems solved by technology

When present in a sufficient concentration, interleukin-1 may cause fever, muscle wasting and sleepiness.
Therapeutic intervention in arthritis is hindered by the inability to target drugs, such as the NSAIDs, to specific areas within a mammalian host, such as a joint.
This is inefficient because transynovial transfer of small molecules from the synovial capillaries to the joint space occurs generally by passive diffusion.
This diffusion is less efficient with increased size of the target molecule.
Thus, the access of large drug molecules, for example, proteins, to the joint space is substantially restricted.
Intra-articular injection of drugs circumvents those limitations; however, the half-life of drugs administered intraarticularly is generally short.
Another disadvantage of intra-articular injection of drugs is that frequent repeated injections are necessary to obtain acceptable drug levels at the joint spaces for treating a chronic condition, such as arthritis.
Exposure of non-target organs in this manner exacerbated the tendency of anti-arthritis drugs to produce serious side effects, such as gastrointestinal upset and changes in the hematological, cardiovascular, hepatic and renal systems of the mammalian host.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gene transfer for studying and treating a connective tissue of a mammalian host
  • Gene transfer for studying and treating a connective tissue of a mammalian host
  • Gene transfer for studying and treating a connective tissue of a mammalian host

Examples

Experimental program
Comparison scheme
Effect test

examples

[0151]The following examples are intended to illustrate the present invention, and should not be construed as limiting the invention in any way.

example i

Packaging of AAV

[0152]The only cis-acting sequences required for replication and packaging of recombinant adeno-associated virus (AAV) vector are the AAV terminal repeats. Up to 4 kb of DNA can be inserted between the terminal repeats without effecting viral replication or packaging. The virus rep proteins and viral capsid proteins are required in trans for virus replication as is an adeno-associated virus helper. To package a recombinant AAV vector, the plasmid containing the terminal repeats and the therapeutic gene is co-transfected into cells with a plasmid that expresses the rep and capsid proteins. The transfected cells are then infected with adeno-associated virus and virus isolated from the cells about 48-72 hours post-transfection. The supernatants are heated to about 56° Centigrade to inactivate the adeno-associated virus, leaving an active virus stock of recombinant AAV.

example ii

Electroporation

[0153]The connective tissue cells to be electroporated are placed into Herpes buffer saline (HBS) at a concentration of about 107 cells per ml. The DNA to be electroporated is added at a concentration of about 5-20 ug / ml of HBS. The mixture is placed into a cuvette and inserted into the cuvette holder that accompanies the Bio-RAD electroporation device (1414 Harbour Way South, Richmond, Calif. 94804). A range between about 250 and 300 volts at a capacitance of about 960 ufarads is required for introduction of DNA into most eukaryotic cell types. Once the DNA and the cells are inserted into the Bio-RAD holder, a button is pushed and the set voltage is delivered to the cell-DNA solution. The cells are removed from the cuvette and replated on plastic dishes.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
timeaaaaaaaaaa
pore sizeaaaaaaaaaa
Login to View More

Abstract

Methods for introducing at least one gene encoding a product into at least one target cell of a mammalian host for use in treating the mammalian host are disclosed. These methods include employing recombinant techniques to produce a vector molecule that contains the gene encoding for the product, and infecting the target cells of the mammalian host using the DNA vector molecule. A method to produce an animal model for the study of connective tissue pathology is also disclosed.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application is a continuation of and claims the benefit of U.S. application Ser. No. 08 / 924 777, filed Sep. 5, 1997, now U.S. Pat. No. 6,156,304 the disclosure of which is incorporated by reference. This is a continuation-in-part application of U.S. application Ser. No. 08 / 381,603, filed Jan. 27, 1995, now U.S. Pat. No. 5,858,355 a continuation-in-part of U.S. application Ser. No. 08 / 685,212, filed Jul. 23, 1996, now U.S. Pat. No. 6,228,356 which is a continuation of U.S. Ser. No. 08 / 027,750, filed Mar. 8, 1993, now abandoned, and a continuation-in-part application of U.S. application Ser. No. 08 / 567,710, filed Dec. 5, 1995, now abandoned which was a continuation of U.S. application Ser. No. 08 / 183,563, filed Jan. 18, 1994, now abandoned, which was a continuation application of U.S. application Ser. No. 07 / 963,928, filed Oct. 20, 1992, now abandoned, which was a continuation application of U.S. application Ser. No. 07 / 630,981, filed D...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K35/00C12N15/09C12N15/63C12N5/00A01N63/00A61K48/00C12N15/00
CPCA01K67/0271A61K38/162A61K48/00A61K48/005A61K49/0008C07K14/54C07K14/545C07K14/715C12N15/8509C12N15/86A01K2217/00A01K2217/05A01K2267/025A01K2267/03A61K38/00C12N2710/10343C12N2710/16643C12N2740/13043C12N2740/13045C12N2750/14143C12N2799/025C12N2799/027A01K2207/15
Inventor GLORIOSO, JOSEPH C.EVANS, CHRISTOPHER H.ROBBINS, PAUL D.
Owner UNIVERSITY OF PITTSBURGH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products